.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
Transpara® Breast AI
Increase cancer detection while enhancing workflow
.webp?width=1000&height=667&name=choosing-transpara-1%20(1).webp)
The Transpara Breast AI Suite
The Transpara Breast AI Suite is a growing hub for automated analysis of mammograms in support of your practice and reading workflow. Transpara solutions work together to provide a clear, concise, and accurate assessment of the mammogram (your ‘second pair’ of eyes), helping you focus on those cases that are most important and triage patients toward the most appropriate supplemental screening modalities.
Why Transpara?
Transpara’s performance has been evaluated in more than 35+ peer-reviewed studies and dozens conference presentations. All of the data on Transpara’s performance – and we have a lot of data – is public, published and readily available.
- Use of Transpara reduced false positives and radiologists’ workload by up to 62.6% in largest Danish screening program; “An Artificial Intelligence–based Mammography Screening Protocol for Breast Cancer: Outcome and Radiologist Workload,” Radiology
- Transpara-assisted workflow helps detect more cancers while safely reducing reading workload by 44% with no change in recall rate; Mammography Screening with AI (MASAI) Study; Lancet Oncology
- The high proportion of cancers with a Transpara score of 10 indicates the promising performance of Transpara, particularly for women with dense breasts. Results on prior mammograms with a Transpara score of 10 illustrate the potential for earlier detection of breast cancers by using AI in screen-reading; “Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases”; European Radiology
Transpara Decision Support is used concurrently to help radiologists read 2D and 3D exams faster with more confidence – all within your current workflow.
The Transpara Exam Score is an image-based risk tool that categorizes exams using a 10-point scale for an overview of the level of suspicion – Elevated, Intermediate, or Low. The higher the score, the higher the risk of cancer in the mammogram. Clinical research conducted with Transpara shows that scores between 1 – 7 (Low Risk) have a 99.97% negative predictive value.
- Use of the Transpara Exam Score in a randomized controlled trial in Sweden show that Transpara-assisted workflow helps detect more cancers while safely reducing workload by up to 44% with no change in recall rate.
- The first time that a breast AI solution is featured in a randomized controlled trial, the study investigated use of AI in breast cancer screening as an alternative to double reading. With AI support, 90% of mammograms classified as “intermediate” or “low” risk and were read by only one reader while the remaining 10% labeled as “elevated” risk were read as usual by two readers.
Transpara’s performance has been evaluated in more than 35+ peer-reviewed studies and dozens conference presentations. All of the data on Transpara’s performance – and we have a lot of data – is public, published and readily available.
- When using Transpara for support:
- Radiologists improved their breast cancer detection performance in mammograms
- Sensitivity increases without increasing false positives
- Radiologists do not lengthen their reading time per exam
- Transpara stand-alone performance is comparable to radiologists
Transpara Breast AI – The globally trusted AI solution
#1
In scientific papers and conference presentations
10M+
mammograms processed
FDA / CE
Cleared and marked
2D/FFDM and 3D/DBT.
Most acquisition, most PACS integration in class
30+
Countries worldwide (in use). Cleared for sale in 40 countries
Transpara Delivers Better
Patient Care
Transpara is used to assist radiologists with the reading of 2D and 3D mammography exams. Transpara provides radiologists with a ‘second pair’ of eyes helping detect cancers earlier and reduce recall rates. Designed to work concurrently with radiologists, research shows that up to 45% of interval cancers can be found earlier using Transpara, while helping to reduce workload and optimize workflow.
Ultimately, this is about providing accurate and consistent breast cancer screening to all women. We work with researchers, radiologists and breast clinicians around the world to continually improve the clinically proven deep learning algorithms in Transpara. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.
Better
Patient
Care
Available directly within your workflow
Transpara is available via many of the systems and platforms you use today, contact your SPM representative for more info.